Walden Biosciences to Fight Kidney Disease With $51 Million Series A

Walden Biosciences Inc. has raised $51 million in venture financing to develop drugs for kidney disease, one of a series of recent investments in a field that has received little venture capital.

Kidney illnesses are common. For example, chronic kidney disease, in which the kidneys can’t filter blood as well as they should, affects 37 million American adults, according to the Centers for Disease Control and Prevention. Conditions such as high blood pressure and diabetes can cause chronic kidney disease.

Kidney…